Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology.
Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials, has closed an equity round of $130 million, a Series C that the company can extend to $200 million by way of a $70 million debt line if it chooses.
Huma raises $130 million to finance its digital health platform
5 hours ago
Huma Therapeutics Limited thas raised approximately $130 million to scale its modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
Huma completes $130m funding round to expand digital ‘hospitals at home’ platform
12th May 2021
UK healthtech company Huma has raised $130m in its latest funding round, in a bid to expand its digital ‘hospitals at home’ platform in the US, Asia and the Middle East.
The Series C funding round was led by Leaps by Bayer and Hitachi Ventures, with new strategic and financial investors also becoming shareholders.
This includes Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as former president of SoftBank Nikesh Arora and chairman of Allianz Michael Diekmann.
Samsung, Sony, Hitachi invest in UK healthtech firm Huma
By IANS |
Published on
Wed, May 12 2021 10:48 IST |
14 Views
Dollar.. Image Source: IANS News
London, May 12 : Samsung, Sony and Hitachi have invested in UK heathtech company Huma Therapeutics Limited in its latest Series C funding round with financing of approximately $130 million, the company said on Wednesday.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw strategic and financial investors like Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz).
Huma This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
UK medtech startup Huma has raised $130 million from German pharma giant Bayer and Hitachi Ventures.
CEO Dan Vahdat says the exciting part of the health tech industry has not yet started.
The industry has been tipped to save up to $3 trillion a year in medical costs by 2030.
A medical technology that aims to place mini hospitals in everyone s pocket has raised $130 million to help fund its push into US, Asia, and the Middle East.
London-based Huma, previously known as Medopad, has raised the funds from a host of big names including German pharma giant Bayer, and the venture funding arm of Japanese tech giant Hitachi.